Get the Stockscreener App
0.286
3.80%
-0.0113
Pre-market:
.2998
0.0138
+4.83%
Dare Bioscience Inc stock is currently priced at $0.286, with a 24-hour trading volume of 416.19K.
It has seen a -3.80% decreased in the last 24 hours and a -40.22% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3024 pivot point. If it approaches the $0.2748 support level, significant changes may occur.
Previous Close:
$0.2973
Open:
$0.29
24h Volume:
416.19K
Market Cap:
$28.77M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-0.6217
EPS:
-0.46
Net Cash Flow:
$-39.49M
1W Performance:
+1.17%
1M Performance:
-40.22%
6M Performance:
-33.33%
1Y Performance:
-71.96%
1D Range:
$0.28
$0.29
52W Range:
$0.27
$1.10
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
11119 North Torrey Pines Road, Suite 200, La Jolla, CA
Dare Bioscience Inc Stock (DARE) Latest News
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
GlobeNewswire Inc.
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
GlobeNewswire Inc.
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
GlobeNewswire Inc.
Daré Bioscience Announces Executive Team and Board of Directors Changes
GlobeNewswire Inc.
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
GlobeNewswire Inc.
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
GlobeNewswire Inc.
Dare Bioscience Inc Stock (DARE) Financials Data
Dare Bioscience Inc (DARE) Net Income 2024
DARE net income (TTM) was -$30.16 million for the quarter ending December 31, 2023, a +2.54% increase year-over-year.
Dare Bioscience Inc (DARE) Cash Flow 2024
DARE recorded a free cash flow (TTM) of -$39.49 million for the quarter ending December 31, 2023, a -117.54% decrease year-over-year.
Dare Bioscience Inc (DARE) Earnings per Share 2024
DARE earnings per share (TTM) was -$0.34 for the quarter ending December 31, 2023, a +6.90% growth year-over-year.
About Dare Bioscience Inc
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.
3.69%
0.93%
Cap:
|
Volume (24h):